Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature

You Wu, Nan Li*, Rong Zhang and Ping Bai

Abstract

Background: This study aimed to analyze the clinical and pathological features of extrauterine endometrial stromal sarcoma (EESS) and explore an effective therapeutic regimen to reduce the recurrence rate in low-grade EESS patients.

Methods: Ten LG-EESS patients who were treated at the Chinese Academy of Medical Sciences Cancer Institute and Hospital from June 1999 to June 2019 were collected and analyzed.

Results: (1) Patient demographics are summarized in manuscript. Preoperative CA125 examination showed that 8 patients had a median level of 49.5 U/L (15.4–168.0 U/L). (2) All ten patients underwent tumor cytoreductive surgery. Five patients underwent optimal tumor resection and achieved an R0 resection. After the initial surgery, 7 patients who had multiple metastasis were treated with adjuvant chemotherapy, 2 patients with vaginal ESS were treated with chemotherapy and radiation therapy, and 6 patients with ER/PR positive received hormone therapy with or without chemotherapy. (2) Most EESS patients had multiple tumors. The omentum was the most commonly affected site, followed by the ovaries. (3) The median follow-up was 94 (range: 27–228) months, and recurrence was observed in 3 patients (n = 10, 30%) who underwent non-optimal surgery and no hormone therapy. The 5-year and 10-year DFS rates were both 70%, as shown in Fig. 2. OS was both 100% at 5 and 10 years.

Conclusion: As a conclusion, EESS is a rare disease and LG-ESS has a good prognosis. Surgery remains the available treatment for patients. LG-ESS has a risk of late recurrence which requires a long-term follow-up. With a limited sample size, our study shows optimal tumor reductive surgery and adjuvant hormone therapy may significantly reduce the risk of recurrence.

Keywords: Extra-uterine endometrial stromal sarcoma, Clinicopathological features, Complete resection, Oral hormonal therapy, Recurrence rate

Background

Endometrial stromal sarcoma (ESS) is a malignant stromal cell tumor that originates from endometrial stromal cells, and it accounts for approximately 1% of uterine malignancies and less than 10% of uterine stromal tumors [1]. ESS usually originates in the uterus, but extra-uterine ESS (EESS), which does not involve the uterus, is also found in clinical practice. Currently, there are two theories that explain the origin of EESS. One theory is that EESS originates from the malignant transformation of endometriosis, and the other theory is that it originates from the malignant transformation of Muller cells, residual cells from embryogenesis that are widely distributed in the peritoneal and pelvic cavities [2, 3]. Malignant endometriosis lesions are mostly endometrioid...
adenocarcinoma or clear cell carcinoma, and EESS is extremely rare [4].

By searching PubMed for literature published between 1970 and 2016 regarding EESS, Alcazar et al. [5] found that among 76 cases of EESS that originated from endometriosis, the most commonly involved sites were ovary (44.3%), pelvic organs outside the uterus and ovaries (15.2%), sigmoid rectum (7.6%), and small intestine (7.6%). Masand et al. [6] also found that the ovaries, small intestine, peritoneum, pelvic cavity, and vagina were the most commonly affected sites. Currently, the clinical treatment for EESS is still controversial. The treatment for two classes of EESS, low-grade ESS (LG-ESS) and high-grade ESS (HG-ESS), is different, in which the former class has a preferable prognosis. Besides intervention of adjuvant therapy, tumor stage and myometrial invasion all contributed to the relapse free survival [7]. The reported overall disease-specific 5-year and 10-year survival rates are 80–90% and 70%, respectively, with a high recurrence risk [8, 9].

Here, we report the study of ten pathologic confirmed LG-ESS patients accepted adjuvant therapy with a follow-up of 27–228 months aiming to determine possible prognosis factors and suggest treatments to potentially reduce EESS relapse.

Method
Patients
The present study included patients with histologically proven low-grade EESS who were admitted and treated at the Chinese Academy of Medical Sciences Cancer Institute and Hospital between June 1999 and June 2019. Thirteen patients were included initially, and the clinical and pathological data were retrospectively reviewed. Ten patients were confirmed with no uterine lesions by surgery and postoperative pathology or preoperative imaging examination (pelvic MR and PET-CT); three patients with a history of uterine surgery were excluded due to difficulties to confirm uterine lesions. Patient information was obtained by searching medical records or telephone calls and questionnaires reach to primary care physicians and/or attending oncologists: age at the time of diagnosis, presenting symptoms and signs, previous history of hysterectomy (if applicable), surgical procedures, pathologic features, and recurrence and survival follow-up information. Institutional review board approval was obtained prior to the initiation of this study.

Treatment protocol
All patients received tumor cytoreductive surgery including resection of both uterine appendages, the omentum, part of the intestinal tube, abdominal and pelvic lymph nodes, or the affected vaginal vulva according their clinicopathological characteristics. Adjuvant treatment was personalized based on the extent of the disease, medical comorbidities, and physician’s recommendation. Adjuvant treatments include chemotherapy, radiotherapy, and hormonal treatment, in combination or alone after per-treatment evaluation. The chemotherapy regimens were PEI (cisplatin + epirubicin + ifosfamide), TC (paclitaxel + carboplatin), and gemcitabine plus docetaxel. Adjuvant radiotherapy was conducted through. Hormone treatment included megestrol (Megace, progestosterone derivative), letrozole (Femara, nonsteroidal aromatase inhibitor), and tamoxifen, which were used mono or combined.

Follow-up
After the completion of the initial treatment, the follow-up was conducted with the treatment in patients. Relapse was defined as the occurrence of new measurable lesion with clinical or imaging evidence and pathologically confirmed. Disease-free survival (DFS) was defined in months as the time from the date of initial surgery to the date of disease relapse. Overall survival (OS) was calculated in months as the time from the date of initial surgery to the date of death from the disease.

Statistical analysis
All statistical analyses were performed using SPSS 23.0 (IBM Corp, Armonk, NY). Data of the current study were presented using the mean, standard deviation, median, range, ratio, and/or frequency. The Kaplan–Meier method was used to generate survival curves and rates.

Results
Patient characteristics
Patient demographics is summarized in Table 1. The median age of the patients at initial diagnosis was 44.5 years (range: 33 to 66 years). Clinical manifestations mainly included lower abdominal discomfort or pain (5/10, 50%), vaginal bleeding (2/10, 20%), dysmenorrhea (1/10, 10%), and pruritus vulvae (1/10, 10%); one patient had no obvious clinical symptoms and was diagnosed during routine physical examination. Four patients had a history of uterine surgery, and pathology results indicated that they all had benign uterine lesions (uterine fibroids or adenomyosis). Preoperative CA125 examination showed that 8 patients had a median level of 49.5 U/L with range from 15.4 to 168.0 U/L, of whom 5 had elevated CA125 levels.

According to surgical records and pathological reports, the tumors lesion in all cases located outside the uterus, with diameters ranging from 5 cm to 20 cm, and most patients had multiple tumors (8/10, 80%) with varying degrees of adhesion to the surrounding tissues or organs.
The tumors were lobulated with capsule formation. Some tumors appeared grayish white with a slightly tough texture, and some appeared grayish pink or grayish brown with a soft texture resembled fish meat. Patients with large tumors had hemorrhagic necrosis and occasional focal cystic changes. Among the eight EESS patients bearing multiple tumors, the omentum was the most commonly affected site, followed by ovaries.

For the morphology of low-grade EESS, most cells were small and round or in a short fusiform shape, which most were atypical, as shown in Fig. 1. The mitotic index was <10/10HPF, and the interstitium was rich in small arterial blood vessels around tumor cells which aligned spirally. As shown in Table 2, among the 10 patients, 2 had localized smooth muscle differentiation, and 7 had definite endometriosis. In addition, 6 were estrogen receptor (ER) positive, 6 were progesterone receptor (PR) positive, and 7 were CD10 positive. Desmin was analyzed in 5 patients with 4 (80%) was negative. Smooth muscle antigen (SMA) were analyzed in 6 patients and 4 (66.7%) were negative.

### Surgical and adjuvant treatment
All ten patients underwent tumor cytoreductive surgery including resection of both uterine appendages, the omentum, part of the intestinal tube, abdominal and pelvic lymph nodes, and the affected vaginal vulva.

### Table 1  Clinical profile of the 10 patients with LG-EESS

| Parameter                        | Number | Percent (%) |
|----------------------------------|--------|-------------|
| Age at diagnosis (median, range) | 44.5   | 33–66       |
| Initial clinical presentation    |        |             |
| Vaginal bleeding                 | 2      | 20          |
| Abd distention                   | 3      | 30          |
| Abd pain                         | 2      | 20          |
| Pruritus vulvae                  | 1      | 10          |
| Dysmenorrhea                     | 1      | 10          |
| None                             | 1      | 10          |
| History of gynecologic surgery   |        |             |
| TAH for leiomyoma                | 4      | 40%         |
| CA125 (median, range), U/ml      | 49.5   | 15.4–168.0  |
| Site of tumor                    |        |             |
| Vaginal wall                     | 2      | 20          |
| Sigmoid                          | 3      | 30          |
| Right ovary                      | 3      | 30          |
| Vulva                            | 1      | 10          |
| Pelvis                           | 1      | 10          |
| Initial surgery                  |        |             |
| Optimal tumor resection (R0 resection) | 5  | 50%         |
| LND                              | 4      | 40%         |
| Stage                            |        |             |
| I                                | 0      | 0           |
| II                               | 2      | 20          |
| III                              | 5      | 50          |
| IIII                             | 3      | 30          |
| Adjuvant treatment               |        |             |
| QT                               | 2      | 20          |
| HT                               | 3      | 30          |
| QT+RT                            | 2      | 20          |
| QT+HT                            | 3      | 30          |
| Follow up (median, range)        | 94     | 27–228      |
| Relapse                          | 3      | 30          |
| Current status                   |        |             |
| AWD                              | 3      | 30          |
| NED                              | 7      | 70          |

*RT Radiotherapy, QT Chemotherapy, HT Hormone therapy, AWD Alive with disease, NED No evidence of disease*
Five patients underwent optimal tumor resection, with no residual tumor seen by the naked eye and achieved a R0 resection. Four patients received para-aortic LND with pelvic LND, and there was no positive observation in lymph nodes. Seven patients who had multiple metastases were treated with adjuvant chemotherapy after the initial surgery; according to the specific conditions, 2 patients with vaginal ESS were treated with chemotherapy and radiation therapy, and 6 patients with ER/PR positive received hormone therapy with or without chemotherapy. The average chemotherapy treatment duration was 6 months, 5.2 courses (range: 4–6). Three patients received only adjuvant hormonal treatment utilizing a variety of agents; the duration of medication used varied from 3 months to 1 year; by analyzing these kind of features, we can find that 2 of them underwent optimal tumor resection, the other with non-optimal surgery; meanwhile, they were all single lesion, and the DFS was 65, 77, and 66 months separately.

**Follow-up**

The median follow-up was 94 (range: 27–228) months, and recurrence was observed in 3 patients (n = 10, 30%). By analyzing the data, 5 patients underwent non-optimal surgery, and recurrence was observed in 3 of them; meanwhile, the relapsed patients received adjuvant chemotherapy combined radiation therapy; none of them received hormone therapy. The other 2 patients had no recurrences, 1 followed by hormone therapy achieved a DFS (disease-free survival) evaluated at 66 months, and the rest followed by chemotherapy combined radiation therapy achieved a DFS at 147 months.

The disease-free interval of relapse was 25, 36, and 60 months, respectively. The recurrences were all developed abdominopelvic, and one patient had ureteral involvement. The 5-year and 10-year DFS rates were both 70%, as shown in Fig. 2. There was no death due to disease progression in all patients. As a result, OS was both 100% at 5 and 10 years.

**Discussion**

The symptom of EESS usually involves abnormal uterine bleeding; however, an accurate diagnosis is more challenging [10]. For patients in our study, three showed abdominal distention, two with vaginal bleeding and two with abdominal pain for initial clinical appearance. To assist diagnosis, preoperative curettage and pathology, including immunohistochemistry test, are import methods [11]. LG-ESS characteristically showed positive for CD10, ER, and PR [7, 12].

In our study, small endometriosis lesions in both vaginal and vulva ESS were found which contradict with previous research [8, 9, 13]. Although there might be issues for specimen collection, a possibility that vaginal or vulva ESS involved malignant transformation of endometrial stromal cells still exists.

The treatment option for LG-ESS involved a total abdominal hysterectomy; however, ovary removal and comprehensive surgical staging including pelvic and para-aortic lymphadenectomy remained debatable [14]. In our study, the patient received radical surgery, which was uterine and double appendage resection plus tumor resection, and achieved optimal tumor reduction with a lower tumor recurrence rate.

Four patients underwent pelvic lymphadenectomy; a postoperative pathology showed negative in lymph nodes. This also supported the findings that ESS usually did not develop lymphatic metastasis [10]. We also did not directly observe the clinical benefit of lymphadenectomy which an analysis of EESS patient showed that the addition of lymphadenectomy to hysterectomy did not improve either cause-specific survival or overall survival compared to hysterectomy alone [15, 16].

For EESS patients of reproductive age, double appendage removal is also recommended [17]. However, a recent study suggested that ovary preservation did not significantly affect the overall survival of patients [15, 18]. In our study, one young patient with LG-ESS underwent fertility preservation surgery (preservation of the normal uterus and appendages) and adjuvant treatment including chemotherapy and hormone therapy. The patient did not relapse in the follow-up with a NED (no evidence of disease) which reached 86 months. Previous studies showed that two patients with vaginal EESS after local tumor resection with negative margins did not relapse in 36-month and 38-month follow-ups [8, 13]. These studies indicate that fertility preservation surgery can be

**Table 2** Pathological characteristics and immunophenotype of 10 patients with LG-ESS

| Parameter                                | Number | Percent (%) |
|------------------------------------------|--------|-------------|
| Tumor diameter (median, range), cm       | 8.7    | 5–20        |
| Localized smooth muscle differentiation   | 2      | 20          |
| Definite endometriosis                   | 7      | 70          |
| ER Positive                              | 5      | 50          |
| PR Positive                              | 5      | 50          |
| CD 10 Positive                           | 7      | 70          |
| Desmin (n = 5)                           | 1      | 20          |
| Positive                                 | 2      | 33.3        |

ER: Estrogen receptor, PR: Progesterone receptor, SMA: Smooth muscle antigen
performed with cautions in EESS patients who follow a desire to retain reproductive ability; however, this conclusion needs to be confirmed with large-sample-size studies.

As discussed in our manuscript, we explore the clinical features of the extrauterine endometrial stromal sarcoma; most of the cases had distant metastasis, refer to ESS; all of them were late stage, but the prognosis was excellent; OS was both 100% at 5 and 10 years. Moreover, there was no recurrence related to lymph node. The pattern of metastasis may be different from ESS; there are two theories that explain the origin of EESS. One theory is that EESS originates from the malignant transformation of endometriosis; one study found that adenomyosis is also found with an incidence of 10 to 18% in EC specimen after surgery, and EC arising from adenomyosis was associated with significantly younger onset ages and better survival than other cases where adenomyosis was just co-existing [19], which is similar with our study. And it also mentions that EC arising from, or just co-existing with, adenomyosis may be a key element to understand also the potential different responses to hormonal drugs. In our study, we also treated patients with hormone drugs, and it may reduce the recurrence rate.

Postoperative adjuvant treatment of EESS includes radiotherapy, chemotherapy, and hormone therapy [20–23]. Our study showed that postoperative radiotherapy and chemotherapy did not reduce the tumor recurrence rate, but hormone therapy, especially for patients who underwent optimal tumor reduction surgery, had significantly reduced recurrence rate compared to that of patients who did not undergo hormone therapy. As a hormone receptor positive tumor, LG-EESS was sensitive for endocrine treatment, as shown by the study [14].

Patients with LG-EESS had a good prognosis and long-term survival but with a risk of late-stage recurrence [24]. In our study, the recurrence rate was 30%, and the longest recurrence duration was 60 months.

**Conclusion**

As a conclusion, EESS is a rare disease, and LG-EESS has a good prognosis. Surgery remains the available treatment for patients. LG-EESS has a risk of late recurrence which requires a long-term follow-up. With a limited sample size, our study shows optimal tumor reductive surgery and adjuvant hormone therapy may reduce the risk of recurrence, but it needs future large epidemiological studies to confirm it.

**Abbreviations**

ESS: Endometrial stromal sarcoma; LG-EESS: Low-grade ESS; HG-EESS: High-grade ESS; DFS: Disease-free survival; OS: Overall survival; ER: Estrogen receptor; SMA: Smooth muscle antigen; NED: No evidence of disease; LND: Lymphadenectomy.

**Acknowledgements**

None

**Authors’ contributions**

YW and NL carried out the studies, participated in collecting the data, and drafted the manuscript. YW and NL performed the statistical analysis and participated in its design. RZ and PB helped to draft the manuscript. All authors read and approved the final manuscript.

**Funding**

None
References

1. Ali RH, Rozbahnani M. Endometrial stromal tumours revisited: an update based on the 2014 WHO classification. J Clin Pathol. 2015;68(5):325–32.

2. Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary extraterine endometrial stromal neoplasms: a clinicopathologic study of 20 cases and a review of the literature. Int J Gynecol Pathol. 1993;12(4):282–96.

3. Jung SJ, Shin SS, Choi C, Hwang EC, Kim SO, Kang TW. Endometrial stromal sarcoma presenting as prevesical mass mimicking urachal tumor. J Korea Med Sci. 2009;24(3):529–31.

4. Khan AW, Craig M, Jarmulowicz M, Davidson BR. Liver tumours due to endometriosis and endometrial stromal sarcoma. HPB. 2002;4(1):43–5.

5. Alcázar JL, Guerriero S, Ajossa S, Parodo G, Piras B, Peiretti M, et al. Extra-genital endometrial stromal sarcoma arising in endometriosis. Gynecol Obstet Invest. 2012;73(4):265–71.

6. Masand RP, Euscher ED, Deavers MT, Malpica A. Endometrioid stromal sarcoma: a clinicopathologic study of 63 cases. Am J Surg Pathol. 2013;37(11):1635–47.

7. Corpa MV, Serafini EP, Bacchi CE. Low-grade endometrial stromal sarcoma presenting as vaginal nodule. Ann Diagn Pathol. 2004;8(5):295–8.

8. Pat J, Mbitanai. Uterine sarcomas. Int J Gynaecol Obstetrics. 2015;131(Suppl 2):S105–10.

9. Arman F, Meoeman P, Cadron I, Neven P, Berteloot P, Vergote I. The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecol Oncol. 2003;90(1):37–43.

10. Cui H, Yuan F, Wang Y, Li X, Zhang Z, Bai H. Clinicopathological characteristics and treatment strategies for patients with low-grade endometrial stromal sarcoma. Medicine. 2017;96(15):e6584.

11. Hwang H, Matsuo K, Duncan K, Pakzamir E, Pham HQ, Correa A, et al. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new. J Clin Pathol. 2015;68(9):710–7.

12. Ronen S, Narula N, Koizumi JH, Hunt B, Giorgiadze T. Low-grade endometrial stromal sarcoma presenting as multiple pulmonary nodules: A potential pitfall in fine needle aspiration and core biopsy specimens - a cytopathological - pathological correlation. Ann Diagn Pathol. 2018;36:38–43.

13. Oliva E, Garcia-Miralles N, Vu Q, Young RH. CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases. Int J Gynecol Pathol. 2007;26(4):359–67.

14. Mizuno M, Yatabe Y, Nawa A, Nakanishi T. Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma. Int J Clin Oncol. 2012;17(4):348–54.

15. Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone JM Jr, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112(5):1102–8.

16. Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99(8):1210–5.

17. Sciallis AP, Bedoske PP, Schoolmeester JK, Sukow WR, Keeney GL, Hodge JC, et al. High-grade endometrial stromal sarcoma: a clinicopathologic study of a group of tumors with heterogeneous morphologic and genetic features. Am J Surg Pathol. 2014;38(9):1161–72.

18. Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005;106(6):1304–8.

19. Lagana AS, Scoscia M. Endometrial cancer in women with adenomyosis: an underestimated risk? Int J Fertil Steril. 2020;14(3):260–1. Published online 2020 Oct 12. https://doi.org/10.22074/ijfs.2020.44413.

20. Oliva E, Egger JF, Young RH. Primary endometrioid stromal sarcoma of the ovary: a clinicopathologic study of 27 cases with morphologic and behavioral features similar to those of uterine low-grade endometrial stromal sarcoma. Am J Surg Pathol. 2004;28(3):305–15.

21. Xie W, Bi X, Cao D, Yang J, Shen K, You Y. Primary endometrioid stromal sarcomas of the ovary: a clinicopathological study of 14 cases with a review of the literature. Oncotarget. 2017;8(38):63345–52.

22. Leath CA, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105(3):630–4.

23. Barrow B, Tward JD, Skidmore T, Gaffney DK. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer. 2009;19(7):1232–8.

24. Liu Z, Ding J, Li X, Yu K. Endometrial stromal sarcoma arising in vagina. Int J Clin Exp Pathol. 2013;6(12):2997–3002.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

This study was approved by the ethic committee of Chinese Academy of Medical Sciences Cancer Institute and Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from the patients.

Consent for publication

Written informed consent was obtained from the patients.

Competing interests

The authors declare that they have no competing interests.

Received: 1 September 2021   Accepted: 13 December 2021
Published online: 13 January 2022